FDA slaps Flori­da's Al­lay Phar­ma­ceu­ti­cals with warn­ing let­ter over vague re­spons­es to drug po­ten­cy is­sues

In­ad­e­quate re­spons­es to find­ings of po­ten­cy dis­crep­an­cies, blend­ing is­sues and out-of-spec­i­fi­ca­tion sam­ples dur­ing a May 2020 in­spec­tion re­cent­ly land­ed tablet man­u­fac­tur­er Al­lay Phar­ma­ceu­ti­cals with a scorch­ing FDA warn­ing let­ter.

In a heav­i­ly-redact­ed ver­sion of the Jan 27 let­ter that was made avail­able this week, the FDA chid­ed the Hialeah, Flori­da man­u­fac­tur­er for vague and in­suf­fi­cient re­spons­es across the board to three ma­jor ob­ser­va­tions dis­cov­ered dur­ing the May 5 to 15, 2020 site in­spec­tion. Those ob­ser­va­tions were com­mu­ni­cat­ed through a Form 483 let­ter, and Al­lay’s re­spons­es to the FDA on June 6 clear­ly irked the agency.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER